Sanofi, Ventyx
Ventyx gets $27 million investment from Sanofi
Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) rose 8.7% to $2.50 yesterday as it announced that French pharma major Sanofi (Euronext: SAN) has agreed to make a $27 million strategic investment in the company]. The closing of the transaction is expected to occur on September 23, 2024.
GlobalData on MSN4d
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m dealUnder the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
Zacks.com on MSN3d
VTYX Stock Rises on Strategic Equity Investment Deal With SNYShares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million ...
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...
Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...
Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...
MedPage Today on MSN2d
Novel Monoclonal Antibody Shows Promise in Ulcerative ColitisTulisokibart is a tumor necrosis factor (TNF)-like cytokine 1A (TL1A) monoclonal antibody with a different mechanism of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback